Zentalis Pharmaceuticals Inc (ZNTL) Stock Price, Quote & News

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4333

Website: zentalis.com

Address:

10275 Science Center Dr., Suite 200, San Diego, United States

G101SPM Jul. 20 at 10:16 AM

$ZNTL $5.07 bid Holding long position at profit https://stocktwits.com/G101SPM/message/616485213 FACT: Zentalis® Pharmaceuticals, Inc. (ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

0 · Reply

acetradingsignals Jul. 20 at 6:47 AM

$ZNTL moving slowly and steadily but nicely on daily chart with key support zone at 4. - 4.25. Next key level to test 5.75 - 6. Currently at 5.15

0 · Reply

SadyK189 Jul. 19 at 10:56 PM

Top Stocks to watch next week $BIYA $FGMC $SDOT $LEDS $ZNTL BIYA: Getting up on 4hours chart. Key support at 4.2 - 4.60. Next key level to test 6.3 - 6.7. Currently at 5.52 LEDS: Initially alerted at 2.14. Currently at 2.89. Looking good on daily chart. Key support zone at 2.05 - 2.25. Next key level to test 3.5 - 3.8. FGMC: Good close of hours candle. Key support zone at 9.8 - 10.40. Next key level to test 14.75 - 15.10. Currently at 13.7 SDOT: Getting up on 4hours chart. key support zone at 17.40 - 18.15. Next key level to test 28.8 - 29.75. Currently at 24.35 ZNTL moving slowly and steadily but nicely on daily chart with key support zone at 4.1 - 4.35. Next key level to test 5.85 - 6.15. Currently at 5.15

1 · Reply

ETAlpha Jul. 19 at 9:55 PM

Riding $SKYQ for weeks!$ZNTL runs from $4.35 floor to $10 PT! Weekend close ($SKYQ $3.80,$ZNTL $5.11). Futes look interesting.$ZNTL $4.35 support holding strong for a right-side squeeze to $10.

0 · Reply

StockScanners Jul. 18 at 8:25 AM

$ZNTL keep watch if this holds above 4.83

0 · Reply

stockpicker63 Jul. 18 at 4:50 AM

🚀 Weekly Results (July 13–17) Strong performance again this week. ⭐ Top Trades: $ZNTL +10.1% $CNMD +9.1% $DINO +8.8% $TRVI +8.7% $ANGO +7.4% 📊 Consistent gains across the board. Discipline. Strategy. Results.

0 · Reply

focafoca99 Jul. 17 at 8:53 PM

$ZNTL Featuring DENALI overall survival data on azenosertib at ESMO in October.

1 · Reply

notreload_ai Jul. 17 at 4:02 PM

Mizuho sees attractive risk-reward in $ZNTL with an Outperform rating and $8 price target. Analyst highlights 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib. https://notreload.xyz/xy/zntl-gets-outperform-from-mizuho-on-azenosertib-potential/

0 · Reply

lucabrix Jul. 17 at 2:52 PM

$ZNTL Here we are!!

0 · Reply

Raph_goss Jul. 17 at 2:26 PM

$ZNTL could this run a way today? Any news insider loading up? What is this?

1 · Reply

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

2026-07-17T08:40:25.000Z - 3 days ago

Zentalis initiated with an Outperform at Mizuho

2026-06-15T11:42:32.000Z - 5 weeks ago

Zentalis assumed with an Outperform at Oppenheimer

Jun 3, 2026, 3:45 PM EDT - 6 weeks ago

Zentalis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 5:00 PM EDT - 6 weeks ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 27, 2026, 4:05 PM EDT - 7 weeks ago

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

May 27, 2026, 8:00 AM EDT - 7 weeks ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

May 26, 2026, 10:00 AM EDT - 7 weeks ago

Zentalis Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 5:39 PM EDT - 2 months ago

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

May 20, 2026, 4:30 PM EDT - 2 months ago

Zentalis Pharmaceuticals Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 2:30 PM EDT - 2 months ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 4:05 PM EDT - 2 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 2 months ago

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

May 12, 2026, 7:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

May 5, 2026, 8:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

May 1, 2026, 5:30 PM EDT - 2 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 10:27 AM EDT - 3 months ago

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

2026-04-17T19:20:16.000Z - 3 months ago

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

Apr 17, 2026, 3:15 PM EDT - 3 months ago

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

2026-04-10T11:01:05.000Z - 3 months ago

Zentalis price target raised to $10 from $6 at Guggenheim

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Apr 9, 2026, 7:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

Mar 26, 2026, 4:05 PM EDT - 4 months ago

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Zentalis Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Zentalis Pharmaceuticals Earnings release: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 9, 2026, 1:00 PM EDT - 4 months ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 4 months ago

Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 12:40 PM EST - 5 months ago

Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 3:30 PM EST - 5 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 4:05 PM EST - 5 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Jan 9, 2026, 6:00 AM EST - 6 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

2026-01-06T13:05:12.000Z - 6 months ago

Zentalis provides update, key milestones in 2025, expectations for 2026

Jan 6, 2026, 8:00 AM EST - 6 months ago

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Nov 12, 2025, 8:00 AM EST - 8 months ago

Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 3:30 PM EST - 8 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T15:05:50.000Z - 8 months ago

Zentalis price target lowered to $4 from $8 at Morgan Stanley

Nov 10, 2025, 4:05 PM EST - 8 months ago

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Nov 10, 2025, 7:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Quarterly report: Q3 2025

Nov 9, 2025, 6:00 PM EST - 9 months ago

Zentalis Pharmaceuticals Slides: Corporate Presentation

Oct 13, 2025, 4:05 PM EDT - 9 months ago

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-09-24T19:40:20.000Z - 10 months ago

Zentalis board member Letai frontrunner to lead NCI, STAT reports

Sep 9, 2025, 7:00 AM EDT - 11 months ago

Zentalis Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:30 PM EDT - 11 months ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 10:15 AM EDT - 11 months ago

Zentalis Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-26T20:10:19.000Z - 11 months ago

Zentalis CLO Andrea Paul to depart, James Bucher to succeed

Aug 26, 2025, 4:05 PM EDT - 11 months ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

2025-08-07T10:27:10.000Z - 1 year ago

Zentalis price target lowered to $5 from $6 at Wells Fargo

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q2 2025

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Jefferies Global Life Sciences Conference

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Zentalis Pharmaceuticals Slides: Jefferies Global Life Sciences Conference

May 27, 2025, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 23, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

May 20, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

2025-05-15T13:07:58.000Z - 1 year ago

Zentalis price target lowered to $9 from $10 at Oppenheimer

May 14, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

2025-04-28T12:11:44.000Z - 1 year ago

Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

2025-03-26T20:25:24.000Z - 1 year ago

Zentalis files $250M mixed securities shelf

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q4 2024

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Annual report: Q4 2024

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Registration statement: Registration Filing

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

2025-03-16T22:40:38.000Z - 1 year ago

Zentalis presents updated clinical data on azenosertib as SGO 2025

Mar 15, 2025, 11:25 AM EDT - 1 year ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Slides: FY 2025

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Slides: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

2025-01-30T13:21:32.000Z - 1 year ago

Zentalis price target lowered to $6 from $8 at Guggenheim

2025-01-30T12:42:35.000Z - 1 year ago

Zentalis price target lowered to $6 from $8 at Wells Fargo

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Press release: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Slides: Study Update

Jan 29, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 28, 2025, 4:05 PM EST - 1 year ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 9, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Dec 12, 2024, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Nov 21, 2024, 1:14 PM EST - 1 year ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 12, 2024, 9:30 AM EST - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q3 2024

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Sep 16, 2024, 7:00 AM EDT - 2 years ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Aug 19, 2024, 4:55 PM EDT - 2 years ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

G101SPM Jul. 20 at 10:16 AM

0 · Reply

acetradingsignals Jul. 20 at 6:47 AM

$ZNTL moving slowly and steadily but nicely on daily chart with key support zone at 4. - 4.25. Next key level to test 5.75 - 6. Currently at 5.15

0 · Reply

SadyK189 Jul. 19 at 10:56 PM

1 · Reply

ETAlpha Jul. 19 at 9:55 PM

Riding $SKYQ for weeks!$ZNTL runs from $4.35 floor to $10 PT! Weekend close ($SKYQ $3.80,$ZNTL $5.11). Futes look interesting.$ZNTL $4.35 support holding strong for a right-side squeeze to $10.

0 · Reply

StockScanners Jul. 18 at 8:25 AM

$ZNTL keep watch if this holds above 4.83

0 · Reply

stockpicker63 Jul. 18 at 4:50 AM

0 · Reply

focafoca99 Jul. 17 at 8:53 PM

$ZNTL Featuring DENALI overall survival data on azenosertib at ESMO in October.

1 · Reply

notreload_ai Jul. 17 at 4:02 PM

0 · Reply

lucabrix Jul. 17 at 2:52 PM

$ZNTL Here we are!!

0 · Reply

Raph_goss Jul. 17 at 2:26 PM

$ZNTL could this run a way today? Any news insider loading up? What is this?

1 · Reply

topstockalerts Jul. 17 at 2:18 PM

$ZNTL the tape looks healthy

0 · Reply

Sillyspuh2 Jul. 17 at 2:17 PM

$ZNTL Not sure why this is running today. No news or filings on the site, and didn't see any other biotech news to warrant the run. Is this just an institutional player loading up?

1 · Reply

Stock_Catcher Jul. 17 at 2:12 PM

$ZNTL new high of day

0 · Reply

NorthernMonkey1 Jul. 17 at 2:09 PM

$ZNTL Run it 🆙️

0 · Reply

nastento Jul. 13 at 2:15 PM

$SGMT $ZNTL my bios for H2 2026 and FY 2027

0 · Reply

WILLWISH Jul. 12 at 6:56 PM

$ZNTL Major catalyst ahead: Topline Phase 2 DENALI data is expected by the end of 2026..

1 · Reply

Broview Jul. 10 at 10:35 PM

$ZNTL 10 bags?

0 · Reply

lucabrix Jul. 10 at 7:19 PM

$ZNTL Big move is coming!

0 · Reply

Broview Jul. 9 at 10:27 PM

$ZNTL promising?

0 · Reply

lucabrix Jul. 6 at 3:05 PM

$ZNTL thanks God Snackdaddy saw ii at 3.55 LOL

0 · Reply

Broview Jul. 4 at 3:48 PM

$ZNTL 10 bags or wipes out?

0 · Reply

MadStockAlerts1 Jul. 1 at 5:50 PM

$SPCX $ZNTL $SNDK $MU $GLXY Our team continues to have a huge winners daily and weekly. We’re giving away free alerts to followers on Stocktwits. We do it for the people. We like to help you all learned, and we learned from you too. What a great community. Look at some of these recent winners, but this is only a few. We’ve had dozens of the last two weeks alone. Join us 🤝

0 · Reply

Market Cap	363.76M
Revenue (ttm)	0.00
Net Income (ttm)	-137.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,554,200
Avg Vol	1,176,458
Day's Range	N/A - N/A
Shares Out	71.19M
Stochastic %K	78%
Beta	1.92
Analysts	Sell
Price Target	$6.67